Focal Segmental Glomerulosclerosis Market 2021 : Know Most Amazing Secrets About The It.
Coherent Market Insights has announced new analysis on Focal Segmental Glomerulosclerosis Status 2021-2027 which has been prepared based on an in-depth market analysis with inputs from industry experts and top vendors in the business. The report covers the market landscape and its development prospects over the coming years. The report also contains a discussion of the key vendors operating in this market.
Focal Segmental Glomerulosclerosis (FSGS) is the rare kidney disease that affects the filtering system (glomeruli) of kidney, causing severe scarring and renal disease at end stage. For instance, as per the Clinical Journal of American Society of Nephrology, 2017 article, incidence rates of FSGS are often high in men, with around 1.5x higher compared with women. The FSGS is characterized with symptoms including edema, proteinuria, increased cholesterol, weight gain, and proteins within blood.
Global Focal Segmental Glomerulosclerosis Market – Drivers
There are no approved drugs as of now for the FSGS treatment. Hence, limited treatment therapy along with government funding for rare diseases’ research are expected to propel the global focal segmental glomerulosclerosis market growth over the forecast period, as no approved drug is presently available to treat FSGS . For instance, both the U.S. Food and Drug Administration (FDA) along with the European Commission, in 2015, granted Sparsentan, a designation of orphan drug to treat FSGS. The Sparsentan is a new drug candidate having dual action mechanism that combines endothelin receptor blockade with angiotensin receptor blockade and is currently under evaluation of Phase III trial, expected to be over by December 2022.
Rising R&D for drugs of FSGS by several manufacturers is expected to fuel the global focal segmental glomerulosclerosis market growth over the forecast period. For instance, the company Pfizer Inc., is going through clinical trial for its PF-06730512 drug evaluation, in adults having primary FSGS. The drug is presently under study of Phase II and is expected to be finished by June 2021.
Furthermore, government investments in the treatment of this rare disease is expected to propel the global focal segmental glomerulosclerosis market growth over the forecast period. For instance, as per the 2017 annual data report by the U.S. Renal Data System, Medicare put in over US$ 34 Bn for patients on dialysis having chronic kidney diseases.
Global Focal Segmental Glomerulosclerosis Market – Restraint
Absence of awareness among the populace regarding the disease along with high dialysis therapy cost is expected to restrict the global focal segmental glomerulosclerosis market growth over the forecast period. For instance, as per the University of Michigan published article in 2017, awareness in patients regarding FSGS is relatively low when patients are in FSGS’s primary stage, this is expected to hamper the global focal segmental glomerulosclerosis market growth over the forecast period.
Global Focal Segmental Glomerulosclerosis Market – Regional Analysis
Based on geography, the global focal segmental glomerulosclerosis market is segregated into North America, Europe, Latin America, Asia Pacific, Africa, and Middle East.
North America is expected to hold a dominant position in the global focal segmental glomerulosclerosis (FSGS) market owing to high FSGS and chronic kidney diseases’ prevalence. For instance, as per the 2017 annual data report from the U.S. Renal Data System, the overall incidence of kidney disease, kidney transplantation, and kidney failure along with dialysis, is highest in the U.S., thereby expected to drive the global focal segmental glomerulosclerosis market growth in this region.
Asia Pacific is expected to register robust growth in the global focal segmental glomerulosclerosis (FSGS) market owing to partnerships and collaboration agreements among several players. For instance, the Indian company Aten Porus’s subsidiary – Oraxion Therapeutics, Inc., is going through efficacy and preclinical study of the ORX-301 drug, which could be used to treat FSGS. Oraxion Therapeutics, Inc., in February 2018, signed an Option Agreement along with the Biopharmaceutical Company based in U.S. and under the agreement, the company receives exclusive rights for the further license and clinical studies of the drug within the U.S.
Global Focal Segmental Glomerulosclerosis Market – Taxonomy
On the basis of Disease Type
-
Secondary Focal Segmental Glomerulosclerosis
-
Primary Focal Segmental Glomerulosclerosis
On the basis of Drug
-
Sparsentan (Phase III)
On the basis of Distribution channels
-
Retail Pharmacies
-
Hospital Pharmacies
-
Online Pharmacies
On the basis of region
-
North America
-
Asia Pacific
-
Europe
-
Latin America
-
Africa
-
Middle East
Major Key Players Include In Focal Segmental Glomerulosclerosis Market: GlaxoSmithKline plc., Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.
Buy instant copy of this research report with Flat US $ 2000 Off@ – https://www.coherentmarketinsights.com/promo/buynow/2224
Main points in Focal Segmental Glomerulosclerosis Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Focal Segmental Glomerulosclerosis Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Focal Segmental Glomerulosclerosis Industry Impact
Chapter 2 Global Focal Segmental Glomerulosclerosis Competition by Types, Applications, and Top Regions and Countries
2.1 Global Focal Segmental Glomerulosclerosis (Volume and Value) by Type
2.3 Global Focal Segmental Glomerulosclerosis (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Focal Segmental Glomerulosclerosis Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Focal Segmental Glomerulosclerosis Market Analysis
Chapter 6 East Asia Focal Segmental Glomerulosclerosis Market Analysis
Chapter 7 Europe Focal Segmental Glomerulosclerosis Market Analysis
Chapter 8 South Asia Focal Segmental Glomerulosclerosis Market Analysis
Chapter 9 Southeast Asia Focal Segmental Glomerulosclerosis Market Analysis
Chapter 10 Middle East Focal Segmental Glomerulosclerosis Market Analysis
Chapter 11 Africa Focal Segmental Glomerulosclerosis Market Analysis
Chapter 12 Oceania Focal Segmental Glomerulosclerosis Market Analysis
Chapter 13 South America Focal Segmental Glomerulosclerosis Market Analysis
Chapter 14 Company Profiles and Key Figures in Focal Segmental Glomerulosclerosis Business
Chapter 15 Global Focal Segmental Glomerulosclerosis Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Editor Details
-
Company:
- CDN Newswire
